Blocking galectin-9/Tim-3 activity in vitro can release Th1 inhibition and lead to a maintained antitumor T cell response, thus improving the clinical efficacy of NPC immunotherapy (129). The gene discussed is LGALS9; the disease is nasopharyngeal carcinoma.